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Abstract. Resistance to chloroquine (CQ) and sulphadoxine-pyrimethamine (SP) led the World Health Organization
(WHO) to recommend changes in national drug policies. The time between policy changes and their implementation
profoundly affects program impact. We developed a model based on data on antimalarial treatments, extracted from
household surveys and national antimalarial policy information from the literature. Drug use in each country during the
time period 1999–2011 and the trend in reduction of CQ use after policy change were estimated. The SP use estimates
were correlated with the prevalence of a molecular marker associated with SP resistance. There was no spatial pattern in
the country-level rate of reduction of CQ use, after policy change. In East Africa SP drug use was strongly correlated to
resistance. If artemisinin resistance spreads to, or emerges in, Africa this methodology will be a valuable tool to estimate
actual drug use and its impact on changes in drug efficacy.
INTRODUCTION
Chloroquine (CQ) was the most frequently used first-line
therapy for uncomplicated Plasmodium falciparum (P.f.)
malaria from the 1940s through to the 2000s.1 As a result of
its high efficacy, good safety profile, and low cost, CQ was a
key part of the 1950s Global Malaria Eradication Program.2
However, factors including funding constraints, lack of politi-
cal support, and the emergence and subsequent spread of
resistance to CQ and the pesticides used in vector control
hampered eradication plans.3 Resistance to CQ was first iden-
tified in the late 1950s, on the Thai–Cambodian border and
concomitantly in South America.4–6 The spread of CQ resis-
tance to Africa ensued, with treatment failures confirmed in
1978 in Kenya and Tanzania,7,8 and later reported in West
Africa in the 1980s.9,10 Despite declining use, CQ remained
the first-line therapy for uncomplicated P.f. malaria in the
majority of sub-Saharan countries until after 2000. An increase
in malaria morbidity and mortality in children < 5 years of age
was observed during this period, and this trend has been
attributed partly to CQ resistance.11,12
During the 1960s, sulphadoxine-pyrimethamine (SP) was
introduced in many countries to replace CQ. Because of a
rapid decline in efficacy in areas of intense use, first in South-
east Asia in the 1970s and later in East Africa in the late
1980s,13 SP was withdrawn from African countries as a first-
line treatment of P.f. malaria between 2003 and 2008. SP
continues to be recommended as an intermittent preventative
treatment of pregnant women14 and more recently as part
of the seasonal malaria chemoprevention in areas of highly
seasonal transmission.15
Over the past decade African countries have transitioned
from CQ or SP to artemisinin-based combination therapies
(ACTs) as a first-line policy for uncomplicated malaria. The
transition from CQ took place in most African countries in
the late 1990s and 2000s (Figure 1). Malawi was the first
African country to change its policy from CQ to SP in 1993.
South Africa was the first country to recommend an ACT
in 2001, whereas Malawi and Botswana were the last to switch
from SP in 2007 (see the animation http://www.wwarn.org/
about-us/news/antimalarial-drug-treatment-policy-developments-
africa illustrating temporal changes in national antimalarial
policies in Africa from 1991 to 2011. Also see Figure 1 and
Supplemental Table 1 in the extra web material).
A reduction in drug pressure has been linked to the return
of CQ susceptibility in several malaria-endemic countries,16
leading to suggestions that the complete removal of CQ may
eventually lead to a return of susceptible parasite popula-
tions. However, CQ usage has continued for many years after
the switch in national policies for the treatment of P.f. In
particular, CQ is still commonly used to treat febrile illness
in children, especially by those who seek treatment in the
private sector.17 Because of the potential influence of this
continued use of ineffective drugs on public health, a stan-
dardized approach for estimating drug use is needed. In this
work, a methodology is proposed for using reports of actual
drug use from publically available household surveys to esti-
mate drug use trends and compare their magnitude in differ-
ent countries. The primary aim of this work was to use the
methodology developed to quantify the changes in common
antimalarials, CQ and SP, both over time and post policy
change. A secondary objective was to correlate measures
of drug use and drug resistance.
METHODS
Data extraction. Drug use data collected between 1999
and 2011 in 40 African countries in Demographic Health
Surveys (DHS)18 and Multiple Indicator Cluster Surveys
(MICS)19 were included in the analysis. The DHS and
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MICS surveys included in this work contained malaria
modules, which ask women within a household to report
on antimalarial use in children under the age of five
within their care, who have experienced fever symp-
toms in the past 2 weeks (see Figure S1 and S2 in the
extra web material for extracts from the DHS and MICS
surveys, respectively).
Quantitative information on antimalarial use, at the indi-
vidual patient level, was extracted as follows:
1. Permission to use the data was obtained, data downloaded
and converted to a format suitable for reading into R,
version 2.12.2.
2. For each survey, an accompanying survey question text
file was obtained. An automated text search in R allowed
extraction of question codes and text related to anti-
malarial questions.
3. The question text from Step 2 was string matched to
common antimalarials using a standardized coding system.
4. The data were loaded into R and individual data stored,
according to the standardized names from Step 3. Where
more than one question was asked about the same stan-
dardized drug code, the data were aggregated.
The DHS and MICS surveys use two-stage cluster sam-
pling techniques in which census areas were selected
with probability proportional to population size within the
main sampling domain identified. Data were extracted at
the individual level to ensure correct sample weighting in
the analyses. When a survey was conducted over a period
of 2 years, the starting year of the survey was used in
the analysis.
National antimalarial policy information was obtained
from the World Health Organization’s Susceptibility of
P.f. to Antimalarial Drugs Report on Global Monitoring
1996–2004, malaria country profiles 2011, World Malaria
Reports 2005 and 2008, and supplemented by a literature
search in PubMed.
Figure 1. Illustration of the timing of antimalarial policy changes in Africa (see Table S1 for more details). The first line policy duration of
CQ, SP, ACT, CQ+SP and AQ+SP are shown in red blue, green, black and light blue arrows, respectively. AQ denotes amodiaquine.
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Drug use aggregation. The sample-weighted number of
children that received drug A in the jth survey (conducted in















where Nij is the number of respondents in survey j from coun-
try i, DijkA is the binary (1 = yes, 0 = no) response to taking
drug A for the kth respondent in the survey, and Wijk is the
corresponding sampling weight for this respondent.
Statistical model. The probability of drug use was modeled
using a mixed-effects logistic regression model, with time as a
linear covariate, measured either as the year post 1999 or as
years after the policy change. The probability of drug A use in
country i and survey j, pijA, was modeled as
logit pijA
 
= a+btj + gi +litj , ð1Þ
where a and b represent the fixed effects intercept and slope,
respectively, whereas gi and li represent the intercept and
slope random effects at the country level, respectively. Includ-
ing random effects allowed the intercept and slope to vary from
country to country: a+ gi and b+li are the country-specific log-
odds intercepts and temporal slope for drug use in the ith
country. It was assumed that YijA is binomially distributed:
YijA ~Binomial Nij, pijA
 
:
Random effects were included so that the intercept and
slope could vary from country to country. The random effects




Summary of Demographic Health Surveys (DHS) and Multiple
Indicator Cluster Survey (MICS) data included in the analysis
DHS MICS
Number of surveys 61 38
Median year 2006 2001
Average CQ use (%) 15.7 35.9
Average SP use (%) 3.5 4.8
Total number of children 121,831 64,703
Number of countries 29 31
Figure 2. Country level drug use estimates from mixed effects model of CQ use where time is measured as post 1999. CQ use is represented
along the horizontal axis. The intercept (that is, CQ use in 1999) is represented by the black square for each country. The red lines show the
change in CQ use from 1999 to 2005 for each country (indicated by the length of the red line). The green line shows the drug use change from
2005 to 2010 (indicated by the length of the green line). The model parameter estimates, standard errors and p-values are given in Table S3.
Countries are ordered by increasing level of their CQ use in 1999 as reflected by their intercept in the mixed effects model.
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represent the heterogeneity between countries for the inter-








Time t, was measured either as the year of the survey
(taken to be the number of years after 1999) or as years after
the policy change from drug A. The model fitting was per-
formed in R, version 2.12.2 and the mixed effects models were
fitted using the lme4 package.
Correlation of drug use and parasite drug resistance.When
drugs are used intensively in a region or a country, selection
of parasites resistant to those drugs is inevitable, especially
when already resistant parasites have evolved in other regions
and could spread to a new location. In this work, we take the
reported drug use estimates as a measure of drug pressure
and correlate these to well-characterized molecular markers
for SP resistance. The relationship between SP use and the
prevalence of those molecular markers in countries that
recommended SP for various lengths of time was explored. A
large database of the prevalence of molecular markers associ-
ated with resistance to SP has previously been created.20 The
prevalence of the mutation dhps540E is indicative of high SP
resistance21 and in other work, a spatiotemporal model was
developed for the spread of the dhps540E marker in Africa.22
Outputs of this model allow estimation of the average
dhps540E prevalence within a country in a given year.
For details of the data used in the dhps540E model see
WWARN’s Molecular Surveyor (http://www.wwarn.org/
resistance/surveyors/molecular).
RESULTS
Data extraction. Ninety-nine surveys from 40 African
countries monitored antimalarial use in children between
1999 and 2011 (Supplemental Table 2). Sixty-one DHS sur-
veys from 29 countries and 38 MICS surveys from 31 coun-
tries were included (Table 1). The MICS surveys were
performed on average earlier than DHS surveys and there-
fore tended to report a higher level of CQ usage. Supplemen-
tal Table 1 summarizes the antimalarial policy changes for
malaria endemic African countries.
CQ. The time plot in Figure S3 shows the percentage usage
of CQ in 94 surveys from 40 countries and shows the general
decrease in use from 1999 to 2011. The mixed effects model
was applied to estimate CQ use in African countries. Figure
S4 A and B show the country-level intercepts and slopes,
respectively, where time was measured as years post 1999.
Figure 2 shows the model predictions for CQ use in each
country in 1999, 2005 and 2010. Figure 3 illustrates in detail
Figure 3. Mixed effects model predictions (red dashed line) for CQ use in Senegal (top left), Nigeria (top right), Ghana (bottom left),
and Sierra Leone (bottom right). The duration of first-line policies for each country is indicated by the arrows across the top of each plot.
The red dots represent the observed CQ use data.
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the mixed effects model predictions for CQ use in four coun-
tries with different trends: Senegal (intermediate starting CQ
use, fast rate of reduction), Nigeria (intermediate starting use,
slow rate of reduction), Ghana (high starting use, fast reduc-
tion), and Sierra Leone (high initial use, slow reduction). The
times at which drug policies changed are given at the top of
each graph for ease of comparing with the trends.
To investigate the overall rate at which CQ use declined
after policy change in Africa as a whole, a logistic regression
model was fitted to the data from the 58 surveys that moni-
tored CQ use, after it was no longer the first line drug (slope =
−0.29, P < 0.001). At this rate of reduction, it would take
2.4 years for the odds of CQ use to fall by 50%.
The trend in CQ use, in each African country after CQ was
no longer the first-line drug, was examined using a mixed
effects model. The country-level intercepts and slopes for
CQ use after policy change, from fitting the mixed effects
model, are shown in Figure S5 A and B. The intercept reflects
the amount of CQ use at the time of policy change, and the
countries are ordered on that basis. Ethiopia and Rwanda
used the lowest proportion of CQ at the time of policy change
and Ghana and Liberia, the highest. Figure 4 visualizes the
changing CQ use post policy change in each country, showing
the predicted use in the year of policy change, 5 years and
10 years after the policy change. The spatial trend of CQ use
reduction in African countries post policy change is illustrated
in Figure S6. There are countries in East andWest Africa with
slow and fast reduction of CQ use, i.e., there is no obvious
spatial pattern in the reduction of CQ use.
SP. From Figure 1 it can be observed that many countries
never recommended SP, but changed directly from CQ to an
ACT. In fact, only nine African countries recommended SP
as a first-line therapy, but Figure S7 shows that actual use of
SP was still common. To estimate SP drug use, a mixed effects
model was fitted using SP use data in all countries. Figure S8
A and B show the country-level intercepts and slopes, respec-
tively, with time measured as post 1999. Figure 5 visualizes the
changing use of SP in each country after 1999 for countries
that recommended SP as a first-line therapy and for which
there is SP use data available, showing the predicted use in
1999, 2005, and 2010.
There was a significant downward trend in SP usage after
policy change from SP to ACTs (logistic regression: slope =
−0.53, P < 0.001). However, at this rate of SP reduction it
would still take 1.3 years for the odds of SP use to fall by
50%. There were insufficient data to fit a mixed effects model
Figure 4. Country-level drug use estimates from mixed effects model of CQ use where time is measured as years post the year of policy
change. CQ use is represented along the horizontal axis. The intercept (that is, CQ use in the year of policy change) is represented by the
black square for each country. The red lines show the change in CQ use 5 years post policy change for each country (indicated by the length
of the red line). The green line shows the drug use change from 5 years to 10 years post policy change (indicated by the length of the green line).
Table S4 gives the model parameter estimates, standard errors, and p-values. Countries are ordered by increasing level of their CQ at the time
of policy change as reflected by their intercept in the mixed effects model.
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to the SP usage data after it was replaced as the recommended
first-line treatment.
Correlation of SP use to SP resistance. The correlation was
assessed between SP use, estimated in this work, and the
changes in a molecular marker, dhps540E, known to be highly
correlated with trends in SP efficacy.21 The prevalence of the
dhps540E genotype at the time of a change to SP is poorly
correlated with SP use (Table 2). Even when reported SP drug
use declined before the change to an ACT, the increase in
drug resistance (using upward trends in molecular marker
prevalence as a surrogate) continued. In East Africa, SP use
and dhps540E prevalence were already high when Malawi,
Figure 5. Country-level drug use estimates from mixed effects model of SP use where time is measured as post 1999. SP use is represented
along the horizontal axis. The intercept (that is, SP use in 1999) is represented by the black square for each country. The red lines show the
change in SP use from 1999 to 2005 for each country (indicated by the length of the red line). The green line shows the drug use change from
2005 to 2010 (indicated by the length of the green line). The model parameter estimates, standard errors, and p-values are given in Table S5.
Countries are ordered by increasing level of their SP use in 1999 as reflected by their intercept in the mixed effects model.
Table 2
Countries recommending SP for which SP usage estimates are available, year of policy changes, and estimated dhps540E prevalence*
Country
National policy change to SP National policy change to ACT
Year SP use (estimated %) dhps540E prevalence (estimated %) Year SP use (estimated %) dhps540E prevalence (estimated %)
Malawi 1993 58 46 2007 13 96
Kenya 1998 41 31 2004 9 91
Zimbabwe 2000 < 1 14 2004 1 26
Burundi 2001 2 41 2003 2 68
DRC 2001 < 1 10 2005 2 33
Tanzania 2001 52 30 2004 23 71
Cote d’Ivoire 2003 2 2 2005 2 3
*The year of policy change to sulphadoxine-pyrimethamine (SP) and later to artemisinin combination therapy (ACT) are both given, along with the estimated SP usage and dhps540E
prevalence in each of these years. The countries are listed in order of the year of policy change to SP. DRC refers to the Democratic Republic of Congo.
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Kenya and Tanzania adopted SP, and dhps540E continued to
increase despite large reductions in SP use. In Zimbabwe,
Burundi, and DRC, drug use was low throughout the period
measured, but increases in dhps540E prevalence were still
observed. Cote d’Ivoire is the exception, where SP drug use
was extremely low (2%) and the dhps540E marker was virtu-
ally absent for the period when SP was the first line drug. The
correlation was measured between drug use and dhps540E
prevalence in the seven countries during the years when SP
was the first line (Figure 6). A strong correlation was observed
in Malawi (r = −0.97, P < 0.001), Kenya (r = −0.91, P = 0.004),
and Tanzania, (r = −0.88, P = 0.12). The remaining countries
did not use enough SP for a relationship to be informative.
ACTs. In the years between 2005 and 2011, 49 surveys
monitoring ACT usage across 31 countries were conducted.
Because of the low number of surveys in each country and the
low reported ACT usage (Figure S9), a mixed effects model
was not fitted, but is postponed until the data set has suffi-
ciently matured. Figure 7 shows the increasing ACT use over
the period of 2005–2011 (regression slope = 0.88, P < 0.001),
compared with the decreasing trends in the use of CQ (regres-
sion slope = −0.13, P < 0.001) and SP (regression slope =
−0.06, P < 0.001).
DISCUSSION
Management of drug resistance is crucial for maintaining
progress in malaria control and realizing the goal of malaria
elimination. One element of effective management is identifi-
cation of foci of resistance and understanding the factors that
shape the trajectory as resistant parasites spread. These factors
can be identified by analyzing the historical and contemporary
data on patterns of resistance to drugs that have already failed
and insight can be gained by modeling those patterns.
Models have been constructed, using the rich data set avail-
able on CQ and SP use in 40 African countries, to define the
trends in actual drug use over time in each country. The
model for CQ use trends post policy change in African coun-
tries showed striking differences in trends even in neighboring
countries. The absence of regional patterns in the rate of
reduction of CQ use suggests that supply and demand side
factors vary considerably by country. With this foundation,
the model can be extended to identify additional factors that
influence the rate of change of drug use.
The model quantifies the lag between the adoption of a
policy for treatment of suspected P.f. infections and the
impact of that policy on actual drug use. The time required
for a 50% reduction in the odds of CQ usage was 2.4 years and
1.3 years for SP.
It has been suggested that the removal of drug selection
pressure can result in the return of parasites susceptible to
the drug,16,23,24 an effect observed when CQ was withdrawn
in Malawi.25,26 However, a decline will not occur if drug usage
continues after a policy change or if other drugs with related
resistance mechanisms exert pressure. For example amodiaquine
use selects for resistance to CQ,27 and the widespread use of
trimethoprim-sulfamethoxazole (Cotrimoxazole) for various
bacterial infections and in prophylaxis for human immunode-
ficiency virus (HIV) acts on the same drug targets as SP.28
The relationship between SP use and drug resistance in key
African countries that recommended SP as a first-line therapy
was investigated. This revealed that Burundi, Zimbabwe, and
the DRC showed moderate prevalence of SP resistance
markers at the time of SP introduction and continued
increases in those markers during the time when SP was the
national policy, but apparently was used very modestly. One
explanation for this is migration of SP-resistant parasites from
neighboring countries in East Africa, such as Kenya, Tanzania,
and Malawi, which have a very high prevalence of SP-resistant
parasites and sustained SP drug pressure. In contrast, Coˆte
d’Ivoire in West Africa is surrounded by countries that show
similar low levels of SP use, and the resistance markers main-
tained low prevalence over the whole period. SP is currently
recommended for chemoprevention14 and appears in most
national guidelines for intermittent preventative therapy for
pregnant women and infants,29 which may help to explain the
prolonged SP usage. The CQ use data have not been analyzed
in light of molecular markers associated with CQ resistance
because, at this time, a comprehensive database of molecular
markers that confer resistance to CQ is yet to be completed.
CQ is not currently recommended as part of the treatment
of P.f. malaria in Africa, and only a handful of countries with
P. vivax recommend CQ. However, CQ usage has persisted
for many years after policy change. Studies have shown that
between 40% and 60% of those who seek treatment of fever
in malaria-endemic countries access drugs in the private sec-
tor, where CQ and SP are up to 25 times less expensive than
an ACT.17 In fact, this price differential was a primary
motivation for the formation of the Affordable Medicines
Facility—malaria (AMFm), a program designed to address
this disparity.30 Furthermore, despite treatment guidelines
that recommend ACTs, SP and CQ remain registered in
many countries and because they are authorized to move
through the marketplace, are highly available.17
There are several limitations of the analysis. First, con-
sumption of antimalarials for laboratory-confirmed malaria
Figure 6. The dhps540E marker prevalence versus the esti-
mated SP drug usage, per country, during SP first line recom-
mendation for Malawi (black), Kenya (red), Zimbabwe (green),
Burundi (dark blue), DRC (light blue), Tanzania (pink), and
Cote d’Ivoire (yellow). DRC refers to the Democratic Republic
of Congo.
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infection might differ from estimates derived from children
with fever. Second, drug use in other age groups may not follow
the same trends as those in children < 5 years of age. Third,
there may be substantial differences in drug use within coun-
tries and these have not been considered. Fourth, there was no
available measure for the quality of antimalarial received.
Finally, some mothers were unable to identify the drugs that
were used, which is likely to underestimate the true usage of
the drugs but would be unlikely to change the main findings.
Countries in Africa have changed antimalarial policy to
ACTs in the last decade, and increasing access to these drugs,
both in the public and private sectors, has been supported by
large initiatives and funding agencies, including Global
Funds, AMFm, the President’s Malaria Initiative, the World
Bank, and UNITAID. Unfortunately, artemisinin resistance
has arisen in Southeast Asia and could spread to, or emerge
in, Africa or Latin America. Moreover, the ACTs artemether-
lumefantrine, amodiaquine-artesunate, and dihydroartemisinin-
piperaquine are now being deployed intensively. Drug
pressure is believed to be an important driver of resistance
and continuous monitoring of usage and efficacy of these
antimalarials is vital to guide policies. Initiatives such as
the DHS, MICS, and ACTwatch will be essential for pro-
viding the necessary data.30 The methods described here will
be a valuable tool to monitor use of ACTs and to identify the
factors that influence actual drug pressure.
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